Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage
Launched by UNIVERSITY OF SAO PAULO GENERAL HOSPITAL · Jun 14, 2018
Trial Information
Current as of May 22, 2025
Unknown status
Keywords
ClinConnect Summary
GASH is a double blind, prospective and randomized clinical trial centered on the University of Sao Paulo General Hospital. Patients will be recruited from neurological/neurosurgical intensive care units. Appropriate ethics and regulatory approvals will be sought for all subjects, according to the International Conference on Harmonization guidelines for good clinical practice (ICH GCP). Investigators will obtain informed written consent from all patients or their legal representative. Recruitment will take place between 2018 and 2019.
Patients will be randomly assigned (1:1) to receive eit...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Radiological confirmatory evidence of an aneurysmal subarachnoid hemorrhage (by digital subtraction angiography, CT angiography, or magnetic resonance angiography)
- • Presentation less than 96 h from ictus
- Exclusion Criteria:
- • Patients taking glibenclamide therapy at presentation
- • Pregnancy
- • Hunt \& Hess V
- • Known renal or hepatic impairment
- • Patient not fully independent before bleed,
- • Strong suspicion of drug or alcohol misuse
- • Patient taking warfarin-type drugs
- • Suspected additional life-threatening disease
About University Of Sao Paulo General Hospital
The University of São Paulo General Hospital (Hospital das Clínicas da Universidade de São Paulo) is a leading clinical research institution in Brazil, renowned for its commitment to advancing medical knowledge and patient care. As an academic hospital affiliated with one of the largest and most prestigious universities in Latin America, it integrates clinical practice, education, and research. The hospital conducts a wide array of clinical trials across various medical disciplines, aiming to develop innovative therapies and improve healthcare outcomes. With a multidisciplinary team of healthcare professionals and access to cutting-edge facilities, the University of São Paulo General Hospital is dedicated to fostering scientific advancements and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São Paulo, Sp, Brazil
Patients applied
Trial Officials
Isabela Windlin
Study Chair
Neuropsicology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials